Print this page
Sarcoma
-
A Randomized, Open-Label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physicians Choice in Participants with Endometrial Cancer Who Have Received Prior Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy.
Protocol: 102404Principal Investigator:
- Aliza Leiser
Applicable Disease Sites: Other Female Genital -
Phase 1/2 Study to Evaluate Palbociclib (IBRANCE®) in Combination with Irinotecan and Temozolomide or in Combination with Topotecan and Cyclophosphamide in Pediatric Patients with Recurrent or Refractory Solid Tumors.
Protocol: 111901Principal Investigator:
- Scott A Moerdler
Applicable Disease Sites: Any Site -
Novel Immune Checkpoint Expression on Circulating Tumor Cells of Sarcomas.
Protocol: 112103Principal Investigator:
- Scott A Moerdler
Applicable Disease Sites: Soft Tissue -
A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients with Osteosarcoma.
Protocol: 112201Principal Investigator:
- Scott A Moerdler
Applicable Disease Sites: Bones and Joints
Lung -
Pediatric Acute Leukemia (PedAL) Screening Trial: Developing New Therapies for Relapsed Leukemias.
Protocol: 112204Principal Investigator:
- Richard A Drachtman
Applicable Disease Sites: Leukemia, not otherwise specified -
A Prospective Phase 3 Study of Patients with Newly Diagnosed Very Low-risk and Low-risk Fusion Negative Rhabdomyosarcoma.
Protocol: 112205Principal Investigator:
- Scott A Moerdler
Applicable Disease Sites: Soft Tissue -
A Phase 1, Multicenter, Open-Label, 2-Stage, Single-Arm Study to Evaluate the Safety and Tolerability of an Autologous Tumor-Infiltrating Lymphocytes (TIL) Regimen and Preliminary Antitumor Activity of TIL in Pediatric, Adolescent, and Young Adult Participants with Relapsed or Refractory Solid Tumors.
Protocol: 112309Applicable Disease Sites: Any Site
-
LIGHTBEAM-U01 Substudy 01A: A Phase 1/2 Substudy to Evaluate the Safety and Efficacy of Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors.
Protocol: 112401-01APrincipal Investigator:
- Richard A Drachtman
Applicable Disease Sites: Any Site -
Phase III Trial of Lomustine-Temozolomide Combination Therapy Versus Standard Temozolomide in Patients with Methylated MGMT Promoter Glioblastoma.
Protocol: 142202Applicable Disease Sites: Brain and Nervous System
- 1
- 2